Lintuzumab Ac-225

Drug Profile

Lintuzumab Ac-225

Alternative Names: 225Ac-HuM-195; 225Ac-lintuzumab; AC225 MOAB M195; Ac225 monoclonal antibody M195; Actimab-A; Actimab-M; Actimab-MDS; Actinium-225 (225Ac)-Lintuzumab; Actinium-225-labelled HuM195; HuM195-Ac-225

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PDL BioPharma
  • Developer Actinium Pharmaceuticals; Baylor Research Institute; Memorial Sloan-Kettering Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Multiple myeloma

Most Recent Events

  • 11 Dec 2017 Interim efficacy and adverse events data from a phase II trial in Acute Myeloid Leukaemia presented at 59th American Society of Hematology Annual Meeting (ASH-2017)
  • 05 Dec 2017 Actinium Pharmaceuticals plans a phase II trial for Myelodysplastic syndrome in USA in 2018
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top